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Abstract
Background: The fish oil-derived ω-3 fatty acids, like docosahexanoic (DHA), claim a plethora of health
benefits. We currently evaluated the antitumor effects of DHA, alone or in combination with cisplatin (CP)
in the EAC solid tumor mice model, and monitored concomitant changes in serum levels of C-reactive
protein (CRP), lipid peroxidation (measured as malondialdehyde;  MDA) and leukocytic count (LC).
Further, we verified the capacity of DHA to ameliorate the lethal, CP-induced nephrotoxicity in rats and
the molecular mechanisms involved therein.
Results: EAC-bearing mice exhibited markedly elevated LC (2-fold), CRP (11-fold) and MDA levels (2.7-
fold). DHA (125, 250 mg/kg) elicited significant, dose-dependent reductions in tumor size (38%, 79%;
respectively), as well as in LC, CRP and MDA levels. These effects for CP were appreciably lower than
those of DHA (250 mg/kg). Interestingly, DHA (125 mg/kg) markedly enhanced the chemopreventive
effects of CP and boosted its ability to reduce serum CRP and MDA levels. Correlation studies revealed
a high degree of positive association between tumor growth and each of CRP (r = 0.85) and leukocytosis
(r = 0.89), thus attesting to a diagnostic/prognostic role for CRP.
On the other hand, a single CP dose (10 mg/kg) induced nephrotoxicity in rats that was evidenced by
proteinuria, deterioration of glomerular filtration rate (GFR, -4-fold), a rise in serum creatinine/urea levels
(2–5-fold) after 4 days, and globally-induced animal fatalities after 7 days. Kidney-homogenates from CP-
treated rats displayed significantly elevated MDA- and TNF-α-, but reduced GSH-, levels. Rats treated with
DHA (250 mg/kg, but not 125 mg/kg) survived the lethal effects of CP, and showed a significant recovery
of GFR; while their homogenates had markedly-reduced MDA- and TNF-α-, but -increased GSH-levels.
Significant association was detected between creatinine level and those of MDA (r = 0.81), TNF-α ) r =
0.92) and GSH (r = -0.82); implying causal relationships.
Conclusion: DHA elicited prominent chemopreventive effects on its own, and appreciably augmented
those of CP as well. The extent of tumor progression in various mouse groups was highly reflected by CRP
levels (thus implying a diagnostic/prognostic role for CRP). Further, this study is the first to reveal that
DHA can obliterate the lethal CP-induced nephrotoxicity and renal tissue injury. At the molecular level,
DHA appears to act by reducing leukocytosis, systemic inflammation, and oxidative stress.
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Review
Cancer ranks second only to cardiovascular disease as a
cause of mortality. There are several treatment modalities
to control cancer. Unfortunately, surgery and radiation are
only effective against local neoplasms. Moreover, chemo-
therapy tends to indiscriminately destroy both normal
and tumor cells, as a consequence of their remarkably low
therapeutic windows. The latter profiles trigger an endless
series of serious adverse reactions that can be life-threaten-
ing. Further, the frequent eruption of resistance to chem-
otherapeutic agents poses a serious challenge to their
efficacy in cancer management. For instance, cispaltin
(CP) is a commonly used cytotoxic agent in the treatment
of numerous solid tumors [1]. However, its clinical use-
fulness is limited by the development of a myriad of
adverse reactions; including a serious, possibly fatal neph-
rotoxicity that is reproducible in many animal models [2].
Hence, the search has unfailingly continued to identify
more promising antitumor agents or combinations that
would preferably exhibit less health hazards [3].
A major aspect of this drug search, therefore, has targeted
natural agents; hoping that they would augment actions
or reduce doses of ordinary chemotherapeutic drugs; thus
improving their overall performance. One of such natural
agent candidates has been docosahexanoic acid (DHA),
an ω-3 fatty acid that is commonly found in cold-water
fish-oil, and some vegetable/algae oils. Naturally, DHA is
a major component of brain gray matter and of the retina
in most mammalian species and is considered essential
for normal neurological and cellular developments [4].
Accordingly, supplemental DHA exhibited a plethora of
health benefits; including protection against cardiovascu-
lar, neurological and neoplastic diseases. The antineoplas-
tic effects of DHA that have been evaluated in animal
models and relevant human trials, showed some hope
that this fatty acid may offer anti-tumor profiles, and
could also enhance the sensitivity of tumor cells to ordi-
nary chemotherapy [5]. Nevertheless, a paucity of infor-
mation is available on its possible combined effects with
CP. Also, because of its nature as a polyunsaturated fatty
acid, the impact of DHA on lipid peroxidation has been
controversial [6]. Besides, thus far, the effects of DHA on
the  in-vivo  growth of Ehrlich cells (breast-cancer-type
cells) have never been sought. Also, the possible diagnos-
tic/prognostic impact of CRP in solid tumor carcinogene-
sis has been poorly understood. Therefore, in EAC-solid
tumor model, we evaluated the chemopreventive effects
of DHA, its impact on that of CP, and the utility of c-reac-
tive protein (CRP) as a diagnostic/prognostic predictor of
this tumor growth and/or responsiveness to chemother-
apy. On the other hand, CP induces substantive nephro-
toxicity that is characterized by renal tubular necrosis,
proteinuria with upregulation of specific signals like TNF-
α, chemokines and cytokines [2]. Therefore, a principal
current interest was to elucidate whether, and how then,
DHA could alleviate this CP-evoked lethal renal dysfunc-
tion in rats.
Drugs and chemicals
Cisplatin (CP): Vials (10 mg/10 mL, each) were obtained
from Merck Co, Egypt. Docosahexanoic acid (DHA):
Obtained from Healthspan Co, UK, as capsules. Each pro-
vides 100 mg of pure DHA. Rat-TNF-α-ELISA kit was pur-
chased from R&D Systems Inc, Minneapolis, Minnesota,
USA).
Trypan blue dye was purchased from Sigma Aldrich
Chemical Co, St. Louis, Missouri, USA. A stock solution
was prepared by dissolving one gram of trypan blue in
100 mL saline. The working solution was prepared by
diluting 1 mL of stock solution with 9 mL of saline. All
other chemicals used, acetic acid, calcium chloride anhy-
drous (CaCl2), calcium chloride dihydrate (CaCl2.2H2O),
disodium phosphate heptahydrate (Na2HPO4.7H2O),
ethylenediaminetetraacetic acid disodium salt dihydrate
(EDTA), heparin, magnesium chloride (MgCl2.6H2O),
methylene blue, potassium chloride (KCl), potassium
dihydrogen phosphate (KH2PO4), disodium basic phos-
phate (Na2HPO4), are all of analytical grade and were
obtained from El-Nasr chemicals company (Abou-Zaabal,
Cairo, Egypt).
Biological resources
Ehrlich ascites carcinoma (EAC) cells
EAC-tumor is of a mammary origin. A spontaneous breast
cancer served as the original tumor from which an ascites
variant was obtained. An ascites rich in tumor cells was
produced by IP inoculation. EAC cells were established in
the Netherlands Cancer Institute. The Ehrlich-tumor cells
were maintained in the laboratory of Faculty of Pharmacy,
Mansoura University, in female Swiss albino mice by
serial IP passage at 7–10 day intervals, as described earlier
[7].
Animals and their treatment outlines
Mice
Female Swiss albino mice weighing 20–30 g were used to
evaluate the anti-tumor activity of the natural com-
pounds. Male mice were not used because of their poor
tumor growth [8].
Rats
Male Sprague-Dawley rats weighing 110–160 g were used
for evaluating the protection of the natural compounds
against CP-induced nephrotoxicity.
The doses used for DHA in this study were in the range of
those used in other studies applied for the same animals.
These were determined after appropriate preliminaryCell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
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experiments. The time course of experiments in this study
was in the range of those used in other studies applied for
the same model of animals. This was determined after
appropriate preliminary experiments.
Evaluation of the anti-tumor profiles of DHA in mice
This was performed by measuring the following parame-
ters:
Monitoring of Tumor size
Female Swiss albino mice were inoculated with EAC cells
and used for evaluating the anti-tumor effects of the natu-
ral agents under investigation. EAC cells were obtained,
counted and diluted as described earlier [9]. After 7–8
days from EAC cell inoculation, ascites fluid was with-
drawn from tumor-bearing mice by needle aspiration
from the peritoneal cavity under aseptic conditions. Fluid
was washed three times with normal saline by centrifuga-
tion at 1000 r.p.m at room temperature (RT). EAC cells
were then tested for viability using trypan blue. The cells
were examined microscopically using a hemocytometer.
Following the viability test, cells were counted under the
microscope. Then, they were suspended in normal saline
so that each 0.1 mL contained 5 × 105 viable cells. Solid
tumors were induced in mice by SC inoculation of 0.1 mL
containing 5 × 105 viable tumor cells on the left flank
anterior to the hind leg [10]. Tumor growth was deter-
mined by caliper measurement of the largest diameter and
its perpendicular [11]. Tumor size was calculated as:
Tumor size (mm3) = 0.5 × a × b2, where a: the largest
diameter and; b is its perpendicular. When the primary
tumor reached a size of 50–100 mm3 (day 0), animals
were divided into the following groups, each composed of
8–10 mice, as follows. All groups were injected with EAC
cells except group (1):
▪ Group (1): (Normal-control group), received CMC, IP,
daily, for 20 days from the 1st day of the experiment (0.2
mL).
▪  Group (2): (EAC-control group), received CMC, IP,
daily, for 20 days from the 1st day of the experiment (0.2
mL).
▪ Group (3): Received CP (5 mg/kg, IP, single treatment
on the 1st day of the experiment), 1 h prior to the injection
of CMC, IP, daily, for 20 days from the 1st day of the exper-
iment (0.2 mL) [12].
▪ Group (4): Received DHA (125 mg/kg, PO for 20 days
from the 1st day of the experiment).
▪ Group (5): Received DHA (250 mg/kg, [13]). It was
given PO for 20 days from the 1st day of the experiment.
▪ Group (6): Received CP (5 mg/kg, IP, single treatment
on the 1st day of the experiment) 1 h prior to the adminis-
tration of DHA (125 mg/kg, PO for 20 days from the 1st
day of the experiment).
The anti-tumor activity was assessed by calculating the rel-
ative tumor volume (rTV) for each individual tumor by
dividing the tumor volume on day 20 (V20) by the tumor
volume on day 0 (V0) multiplied by 100% [14].
Lipid peroxides, measured as thiobarbituric acid reactive species 
(TBARs)
TBARs, mainly malondialdehyde (MDA) were measured
according to the reported methods [15]. In this assay,
thiobarbituric acid reacts with MDA in acidic medium at
95°C for 30 min. to form thiobarbituric acid reactive
product. The absorbance of the resultant pink product can
be measured at 534 nm. For this purpose, blood was col-
lected and allowed to clot, then centrifuged at 2,000 r.p.m
for 15 min. at 4°C. The top yellow serum layer was pipet-
ted off without disturbing the white buffy layer. MDA was
assayed in the same day. Linearity of the reaction was up
to 100 nmol/mL.
Serum C-reactive protein (CRP) level
CRP was assayed according to the reported methods [16].
A kit obtained from Spinreact Co, Spain, is used. The CRP
reagent is a suspension of polystyrene latex particles,
coated with goat IgG anti-CRP. When CRP is present in
the sample (mouse serum), the presence of agglutination
indicates a level of CRP equal to or greater than 6 mg/L.
Leukocytic count
White blood cell (WBC) count was estimated using hemo-
cytometer apparatus, according to the reported methods
[17].
The effect of DHA on CP-induced nephrotoxicity in rats
As reported in the literature, nephrotoxicity can be
induced by injecting CP (7–10 mg/kg, IP, single dose
[6,18]. In the present study, a dose of (10 mg/kg) was cho-
sen after preliminary experiments. This evoked a signifi-
cant increase in serum urea and creatinine levels after 7
days from the start of the experiment (3 days after CP
injection). After 10 days, all the animals treated by CP
alone died. Hence, the rats were divided into the follow-
ing groups (8 rats each):
▪ Group 1: (Control group), received 0.4 mL of CMC, IP,
for 7 days.
▪ Group 2: Received CP (10 mg/kg, IP, on the 4th day of
the experiment) 1 h prior to the injection of 0.4 mL of
CMC, IP. The animals received 0.4 mL of CMC, IP, for 7
days from the 1st day of the experiment.Cell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
Page 4 of 17
(page number not for citation purposes)
▪ Group 3: Received CP (10 mg/kg, IP, on the 4th day of
the experiment) 1 h prior to the administration of DHA
(125 mg/kg, PO, for 7 days from the 1st day of the experi-
ment).
▪ Group 4: Received CP (10 mg/kg, IP, on the 4th day of
the experiment) 1 h prior to the administration of DHA
(250 mg/kg, [19]). DHA was given PO for 7 days from the
1st day of the experiment.
▪ Group 5: Received CP (10 mg/kg, IP, on the 4th day of
the experiment) 1 h prior to the administration of DHA
(250 mg/kg, PO, for 10 days from the 1st day of the exper-
iment).
▪ Group 6: Received DHA (250 mg/kg, PO, for 10 days
from the 1st day of the experiment).
After the end of the specified period of the experiment (7
or 10 days), the animals were anesthetized using ether,
and then blood samples were collected, as mentioned pre-
viously, to separate serum samples for assaying urea and
creatinine. Finally, the animals were sacrificed and kid-
neys were quickly removed and washed in ice cold isot-
onic saline, decapsulated, dissected, decorticated,
weighed and minced. A 10% (w/v) homogenate was
made in PBS (pH 7.4). The homogenate was centrifuged
at 6000 r.p.m for 10 min. at 4°C and the supernatant was
removed and stored on ice for assay of reduced glutath-
ione (GSH) and lipid peroxides as MDA.
For the groups terminated after 7 days, survival studies
were also performed using similar, but separate, groups
treated for 10 days. This treatment period was judged by
preliminary studies based on the survival of animals in
the CP-group. The following parameters were evaluated:
Measuring kidney glomerular function
It was estimated through the following parameters:
Serum creatinine
Creatinine was measured in rat sera kinetically [20]. The
assay depends on that creatinine in alkaline solution
reacts with picrate to form a colored complex. The rate of
complex formation is measured photometrically at 492
nm. A kit from Dp International Co, Egypt was used.
Serum urea
Urea was measured enzymatically in rat sera according to
the reported procedures [21]. A kit from El-Nasr Co, Egypt
was used.
Glomerular filtration rate
Glomerular filtration rate was estimated by measuring the
renal plasma clearance of inulin (Cinulin). Concentration
of inulin was measured in urine and plasma samples after
precipitation with 10% TCA; and clearance values were
expressed in mL/min/100 g of initial body weight, accord-
ing to the reported procedures [22].
Urine total protein (proteinuria)
The urine samples were collected over twenty four hours
from rats placed in metabolic cages.
Urinary protein concentration was measured using the
Lowry assay [23].
Measuring systemic inflammation, oxidative stress and the anti-
oxidant potential in kidney homogenates
They were evaluated by measuring the following parame-
ters:
Tumor necrosis factor-alpha (TNF-α)
TNF-α was quantitated by ELISA, using an ELISA assay
(Quantikine Rat TNF-α kit; R&D Systems Inc., Minneapo-
lis, Minnesota, USA). Kidney tissue was homogenized in
PBS containing 0.05% Tween-20. Aliquots containing 300
μg of total protein were used for the TNF-α assay accord-
ing to the protocol of the manufacturer.
Lipid peroxides measured as TBARs (MDA)
MDA was measured by the same method used in assaying
serum MDA level in mice except that the sample was kid-
ney homogenates. Homogenates were prepared right after
the animals were killed and kept on ice. MDA was assayed
in the same day.
Reduced glutathione (GSH)
It was measured in rat kidney homogenates according to
the reported procedures [24]. The method is based on the
reduction of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB)
with GSH to produce a yellow compound. The intensity of
color is directly proportional to GSH concentration and is
measured at 405 nm. A kit obtained from Biodiagnostic
Co, Egypt, was used to measure GSH. Linearity of the reac-
tion is up to 120 mg/dL (4 mmol/L).
Statistical analysis
Statistical significance between two groups was evaluated
by Student's t-test for unpaired data. Comparison among
multiple groups was conducted using one-way analysis of
variance (ANOVA) followed by Tukey's post hoc test to
determine significance among the means of the data
groups. Linear regression equation was used for curve fit-
ting and determination of the correlation coefficient "r".
X2  test was applied to compare the survival number
between different groups. Statistical significance was pre-
defined at P < 0.05.Cell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
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Results
Induction of solid tumor in mice was accompanied by
marked cellular, molecular, and biochemical changes that
included leukocytosis, elevation of serum c-reactive pro-
tein (CRP), and enhanced lipid peroxidation. The latter
free radical was measured as malondialdehyde; MDA.
These parameters were utilized as sensors for the extent of
tumor development and/or DHA-induced chemopreven-
tion (Figures 1, 2, 3, 4). Thus, relative to normal control
mice, inoculation of EAC-cells led to the development of
a solid tumor after 2 weeks. Treatment with the cytotoxic
drug, cisplatin (CP, 5 mg/kg) led to a 55% reduction in
tumor size (p < 0.05). Likewise, treatment with DHA (125
mg/kg) evoked a 38% inhibition in tumor growth (p <
0.05), a response that was; however, significantly lower
than that of CP (p < 0.05). By contrast, a higher dose of
DHA (250 mg/kg) strikingly suppressed tumor growth, by
79%, (p < 0.05); a cytotoxic response that appreciably sur-
passed that produced by CP (p < 0.05). Combining the
lower dose of DHA (125 mg/kg) with CP significantly
enhanced the chemopreventive effects of both drugs than
either of their individual responses (81% inhibition of
growth, P < 0.05). Figure 2A indicates that EAC evoked a
2-fold rise in leukocytic count, a primary antecedent
inflammatory response in the process of carcinogenesis.
CP evoked reduction from both the normal control (leu-
kopenia) and the EAC-control group. The lower DHA
dose (125 mg/kg) reduced leukocytosis from that of the
solid tumor level, yet it still remained higher than either
of the CP or the control levels (p < 0.05). Increasing DHA
to 250 mg/kg also reduced the EAC-induced leukocytosis
virtually to the baseline level (P < 0.05). When the low
dose DHA was combined with CP, both drugs reduced the
leukocytic count to the baseline level, thus avoiding leu-
kopenia seen with CP. Correlation studies that utilized
data obtained for tumor-size and leukocytosis (Figure 2B)
suggest a high degree of a significant positive association
between the two phenomena (r = 0.89).
The diagnostic/prognostic role of C-reactive protein
(CRP) has been sought in some types of cancer; though
reports are still divisive [25]. Here, EAC brought about
almost 11-fold rise in that protein level. This response was
attenuated by CP to 6.0-fold of control level (P < 0.05).
Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg/single dose) on the rate of EAC-solid tumor growth in mice Figure 1
Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg/single dose) on the rate of EAC-solid tumor growth in 
mice. Solid tumors were induced by SC inoculation of viable tumor cells on the left flank anterior to the hind leg till a tumor 
size of 50–100 mm3 was obtained. Animals were then injected with the above drugs for 20 days. Tumor size was calculated as 
a percentage of relative tumor size (day 20/day 0) for each individual tumor. Data of different groups were normalized to that 
of the EAC-control group. Symbols indicate significance against; # CP-treated group; ° normal control group; and * EAC-con-
trol group.
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DHA (125 mg/kg) also reduced CRP level (P < 0.05) than
that of the EAC-group, down to 8-fold above the baseline.
This remained however significantly less potent than the
CP response (P < 0.05). Notably, a more substantive
reduction, down to 2.5-fold, was obtained by the higher
DHA dose (250 mg/kg). The latter response was reproduc-
ibly achieved by combining CP with the low dose DHA
(125 mg/kg). To validate the significance of this protein in
evaluating tumor progression or responsiveness to cyto-
toxic agents, correlation curve was constructed between
tumor size and CRP level for the various mice-treated
groups. As can be seen in figure 3B, a high positive associ-
ation linear regression curve was produced (r = 0.85). On
the other hand, the level of lipid peroxides (LPO), in
terms of MDA, was estimated as a measure of oxidative
stress in mouse sera (Figure 4). MDA significantly rose
along with the induction of EAC-solid tumor (2.75 fold).
Though this level was reduced significantly by CP (down
to 2.0-fold, P < 0.05), it was still markedly higher than the
baseline (P < 0.05). DHA (125 mg/kg) showed a better
response than CP (p < 0.05), thus lowering MDA to a 0.5
fold above baseline (P < 0.05). Animals that received
higher DHA dose (250 mg/kg) had LPO levels similar to
those of the control animals. Correlation studies between
MDA and tumor size, showed insignificant positive asso-
ciation between the two parameters (r = 0.52; data not
shown).
A seriously known adverse reaction to CP in clinical set-
tings is its nephrotoxicity, an also well-established drug-
induced nephrotoxicity animal model. Thus, a single CP
dose (10 mg/kg, injected IP, injected on the 4th day)
induced lethal nephrotoxicity in rats after a total of 7 days.
This was indicated by disruption of renal function, as
reflected by substantially elevated serum levels of urea (5
fold) and creatinine (2.5 fold) after 7 days (P < 0.05) (Fig-
ures 5A, 5B). This was accompanied by a global animal
fatality after 10 days. At day 7, animals that had received
DHA (125 mg/kg) or (250 mg/kg) did not show improved
glomerular filtration rates (Figure 6A) and had persist-
ently mounting proteinuria (Figure 6B). However, as evi-
dent from figure 6-C, resuming treatment for 10 days
rescued 88% of the rats that only received the higher DHA
dose (250 mg/kg). This was also consonant with an appre-
ciable reduction in levels of both urea and creatinine, as
compared to the CP-treated rats (Figures 5A, 5B). Control
(A) Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg/single dose) on the EAC-induced leukocytosis in mice Figure 2
(A) Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg/single dose) on the EAC-induced leukocytosis in 
mice. Solid tumors were induced and animals were treated as under Figure-1. After 20 days, blood was collected and leuko-
cyte count was determined by means of a hemocytometer. Average counts of different groups were normalized to that of the 
normal control group. Symbols indicate significance against; # CP-treated group; ° normal control group; and * EAC-control 
group. (B): Correlation between leukocytic count and tumor size in EAC-solid tumor bearing mice that had been treated with 
DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose). r denotes the correlation coefficient obtained for the linear 
regression line.
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(A) Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose) on serum C-reactive protein (CRP) level in EAC-solid  tumor bearing mice Figure 3
(A) Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose) on serum C-reactive protein (CRP) 
level in EAC-solid tumor bearing mice. Solid tumors were induced and animals were treated as under Figure-1. After 20 
days, blood was collected and sera separated for determining the level of CRP. Means of data for different groups were nor-
malized to that of the normal control group. Symbols indicate significance against; # CP-treated group; ° normal control group; 
and * EAC-control group. (B): Correlation between CRP and tumor size in EAC-solid tumor bearing mice that had been 
treated with DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose). r denotes the correlation coefficient obtained for the 
linear regression line.
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animals that had received only DHA (without CP)
showed no change in their renal function tests nor were
their survival threatened as well.
Oxidative stress is a hallmark of CP-induced nephrotoxic-
ity [26]. Also, DHA is a polyunsaturated fatty acid with
reportedly inconsistent effects on LPO [5]. Hence, we
focused on evaluating the effects of DHA on MDA, as well
as on reduced glutathione (GSH; a crucial endogenous
anti-oxidative/membrane preserving thiol) in kidney
homogenates from variously treated rats. Figure 7A points
out that after 7 days of treatment, CP almost doubled the
level of MDA in rat kidney homogenates. This responsive-
ness remained unchanged when CP was combined with
DHA (125 or 250 mg/kg) for this treatment period.
Resuming DHA treatment for 10 days, however, resulted
in a remarkable reduction in MDA level to near control
levels (p < 0.05 against CP). To gain insights into possible
causal relationships of lipid peroxidation in disruption of
GFR, correlations were made between MDA and creati-
nine levels. Figure 7B demonstrates that a considerable
positive association exists between the MDA level and cre-
atinine, in response to various drug treatments (r = 0.81).
This indicates that reduction of renal MDA level contrib-
utes to renal function protection. On the other hand,
treatment with CP significantly depleted (GSH) level in
kidney homogenates. Concurrent treatment with DHA
(250 mg/kg) restored GSH to near normal concentrations
in kidney tissues (p < 0.05; against CP) (Figure 8A). Fur-
ther, a high degree of negative association between GSH
and creatinine levels was observed (Figure 8B, r = -0.82),
thus confirming an active role for GSH in the mechanisms
governing both renal tissue injury by CP (lower levels),
and protection therefrom by DHA (higher levels).
Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose) on serum lipid peroxide level (measured as MDA) in  EAC-solid tumor bearing mice Figure 4
Effect of DHA (125, 250 mg/kg/day) and/or CP (5 mg/kg, single dose) on serum lipid peroxide level (measured 
as MDA) in EAC-solid tumor bearing mice. Solid tumors were induced and animals were treated as under Figure-1. After 
20 days, blood was collected and sera separated for determining the level of MDA. Average data of different groups were nor-
malized to that of the normal control group. Symbols indicate significance against; # CP-treated group; ° normal control group; 
and * EAC-control group.
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Renal inflammation is a primary antecedent in impaired
renal diseases; as currently exemplified by the CP-evoked
nephrotoxicity [2]. Accordingly, we assessed levels of TNF-
α, a marker of systemic inflammation, in renal tissues
treated with and without CP, DHA and their combina-
tions. Figure 9A shows that CP evoked ~10-fold rise in
renal tissue TNF-α levels after 7 days. Co-treatment for
this same period with DHA (either 125 or 250 mg/kg)
failed to effectively reduce TNF-α levels from those
attained with CP-group. Conversely; however, extending
the co-treatment period with 250 mg/kg of DHA for 10
days blunted the rise in TNF-α levels (p < 0.05). Figure 9B
further demonstrates that the rise in TNF-α level (inflam-
mation) highly correlated with that of serum creatinine
(renal dysfunction) (r = 0.92). These findings suggest that
TNF-α is both a key trigger of nephrotoxicity in response
to CP treatment, and a crucial target in alleviation of such
anomalies by DHA.
This study was the first to seek the anti-tumor capacity of
DHA on EAC-solid-tumor model in mice. Mice were
treated with two doses of DHA (125, 250 mg/kg) for 20
days, either alone or in combination with CP (5 mg/kg,
single treatment). DHA alone showed anti-tumor activity,
indicated by a significant reduction in tumor size, as com-
pared to the EAC-control group. The higher dose of DHA
(250 mg/kg) evoked a greater anti-tumor activity, indicat-
ing that the anti-tumor activity of DHA is dose-depend-
ent. The combination of DHA with CP boosted the anti-
tumor capacity of CP, as indicated by a more significant
reduction in tumor size, relative to the CP-group. This was
in agreement with earlier findings which showed that
DHA enhanced the activity of some anti-cancer drugs,
such as anthracyclines [4]. It also appears that DHA
improves the overall biological profiles of CP; as seen
with leukocytosis in this study where a 2 fold-rise was
obtained. Leukocytic count often increases in cancer
patients, and has been known as a paraneoplastic syn-
Effect of DHA (125, 250 mg/kg/day) on CP (10 mg/kg, single dose)-induced renal dysfunction in rats Figure 5
Effect of DHA (125, 250 mg/kg/day) on CP (10 mg/kg, single dose)-induced renal dysfunction in rats. DHA was 
given throughout day1-day7 (or day1-day10) of the experiment; depending on animal survival. CP was given on day4. Blood 
was collected and sera separated for measurements of creatinine (5A) and urea (5B) levels, after 7 or 10 days; depending on 
animal survival. Data of different groups are expressed as mean +/- SEM of individual animal levels. Symbols indicate significance 
against; respective *CP-treated group; and °control group.
0
0.5
1
1.5
2
2.5
3
 Control CP 10mg/kg
7days
CP+DHA 125
mg/kg 7days
CP+DHA
250mg/kg
7days
CP+DHA
250mg/kg
10days
S
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
 
(
m
g
/
d
L
)
°°
°
*
°Cell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
Page 10 of 17
(page number not for citation purposes)
Effect of DHA (125, 250 mg/kg/day) on CP (10 mg/kg, single dose)-induced impairment of GFR (6A), and proteinuria (6B) in  rats Figure 6
Effect of DHA (125, 250 mg/kg/day) on CP (10 mg/kg, single dose)-induced impairment of GFR (6A), and pro-
teinuria (6B) in rats. DHA was given throughout day1-day7 (or day1-day10) of the experiment; depending on animal sur-
vival. CP was given on day4. Data of different groups are expressed as mean +/- SEM of individual animal levels. 6C shows 
animal survival after 7 and 10 days following different drug-treatments. (6C): survived animal % after 7 and 10 days of different 
drug-treatments. Symbols indicate significance against; respective *CP-treated group; and respective °control group.
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(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on MDA level in rat kidney homogenates Figure 7
(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on MDA level in rat kidney homoge-
nates. DHA was given throughout day1-day7 (or day10) of the experiment; depending on animal survival. CP was given on 
day4. Animals were sacrificed, kidneys removed and homogenates prepared. Data represent means +/- SEM of individual MDA 
levels in different groups, expressed as a percentage of the control group. Symbols indicate significance against; *CP-treated 
group; and °control group. (B): Correlation between MDA and creatinine levels in rat kidney homogenates treated with CP (10 
mg/kg, single dose) and/or DHA (125, 250 mg/kg/day). r denotes the correlation coefficient obtained for the linear regression 
line.
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(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on reduced glutathione (GSH) level in rat kidney  homogenates Figure 8
(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on reduced glutathione (GSH) level in 
rat kidney homogenates. DHA was given throughout day1-day7 (or day10) of the experiment; depending on animal sur-
vival. CP was given on day4. Animals were sacrificed, kidneys removed and homogenates prepared. Data represent means +/- 
SEM of individual GSH levels in different groups, expressed as a percentage of the control group. Symbols indicate significance 
against; *CP-treated group; and °control group. (B): Correlation between GSH and creatinine levels in rat kidney homogenates 
treated with CP (10 mg/kg, single dose) and/or DHA (125, 250 mg/kg/day). r denotes the correlation coefficient obtained for 
the linear regression line.
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(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on TNF-α level in rat kidney homogenates Figure 9
(A) Effect of DHA (125, 250 mg/kg/day) and CP (10 mg/kg, single dose) on TNF-α level in rat kidney homoge-
nates. DHA was given throughout day1-day7 (or day10) of the experiment; depending on animal survival. CP was given on 
day4. Animals were sacrificed, kidneys removed and homogenates prepared. Data represent means +/- SEM of individual TNF-
α levels in different groups. Symbols indicate significance against; *CP-treated group; and °control group. (B): Correlation 
between TNF-α and creatinine levels in rat kidney homogenates treated with CP (10 mg/kg, single dose) and/or DHA (125, 
250 mg/kg/day). r denotes the correlation coefficient obtained for the linear regression line.
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drome that occurs occasionally in patients with oral
malignancies [27]. Albeit CP reduced leukocytosis in our
EAC-model, it further led to a marked leukopenia; which
goes well with the known bone marrow suppressive
potential known for CP. This leukopenia was abolished
when DHA was jointly given with CP. This concerted
action therefore would help maintain the integrity of the
immune system.
The obviously reported positive association between can-
cer and inflammation suggests a potential role for CRP
and leukocytosis as possible indicators of cancer develop-
ment. However, until very recently, a paucity of informa-
tion was available as to whether CRP can serve as a
prognostic or diagnostic factor in cancer. This information
was also often inconsistent and appear to be cancer-type
specific. For instance, some studies provided a modest evi-
dence for a positive diagnostic role of CRP in cancer [28].
Conversely, some researchers found that elevated plasma
CRP concentration appears to be a strong predictor of
poor survival and lower probability of prostate-specific
antigen response to treatment in patients with androgen-
independent prostate cancer [29]. The CRP role as a pre-
dictor of survival has been shown in multiple myeloma,
melanoma, lymphoma, and various ovarian-, renal-, pan-
creatic-, and gastrointestinal-tumors [25]. Others sug-
gested that the pre-operative serum elevation of both IL-6
and CRP are good prognostic predictors in colorectal can-
cer patients [30]. In addition, a few studies reported that
some tumor-based events, such as expression of IL-6
receptor and COX-2 enzyme, or infiltration of T-lym-
phocytes, are inferior to CRP in determining survival in
patients with localized renal cell carcinoma [31].
Accordingly, this work developed an interest to study the
correlation between CRP level and the progression of
EAC-solid-tumor. Here, it was the first time ever to study
the correlations between tumor size, leukocytic count and
serum CRP level in the EAC-solid-tumor model. We
found that leukocytic count and CRP level were signifi-
cantly increased in response to a mount in tumor size.
Further, treatment with CP and DHA showed a significant
reduction in the tumor size that was paralleled with a fall
in both CRP level and leukocytosis. The correlation curves
we constructed indicated a high degree of positive associ-
ation between tumor size and both of CRP level and leu-
kocytic count (r = 0.85 and 0.89; respectively), thus
supporting our hypothesis that CRP may well serve as a
prognostic and/or diagnostic factor in this tumor model.
Thus, both the extent of tumor progression, as well as the
prediction of responsiveness to chemotherapy may well
be inferred through CRP measurements.
Overall, the in vivo epidemiological and experimental
studies have not yet clearly conferred a strong evidence for
clinically beneficial effects of ω-3 polyunsaturated fatty
acids (PUFAs) in breast cancer. However, some evidence
was revealed by in vitro studies or by limited clinical work
that ω-3 PUFAs may reduce the risk of breast cancer devel-
opment [32]. A more recent study indicated that ω-3
PUFAs decrease cell proliferation and induce apoptotic
cell death in human breast cancer cells, possibly by
decreasing signal transduction through the Akt/NF-κB cell
survival pathway [33]. In addition, dietary intake of ω-3
PUFAs was shown to reduce growth and metastasis of
mammary tumors [34]. Because EAC is a breast-cancer-
related tumor, our present results favor a promising pro-
file for DHA against breast cancer, at least when combined
with traditional chemotherapeutic agents like CP.
On the other hand, the selectivity of DHA and other
PUFAs on tumor cells has been a worthwhile goal of
research. In this context, in vitro cell culture studies have
led to a consensus that some PUFAs exert a selective cyto-
toxic or anti-proliferative effect on tumor cells rather than
on normal cells [35]. The cellular protective effects of
DHA were also investigated by some studies. Thus, DHA
was found to protect neuronal cells from apoptosis by
inhibiting the activity of caspase enzyme [36].
On the contrary, several studies have been divisive over
the ultimate effects of DHA/PUFAs on lipid peroxidation
and its sequaleae. These FAs, themselves, can undergo per-
oxidation with free oxygen, to produce lipid hydroperox-
ides, which in turn propagate further peroxidation into
peroxy and alkoxy radicals. The latter compounds may
break down to cyclic endoperoxides and MDA-like prod-
ucts. LPO is capable of affecting cell proliferation due to
the formation of inter- and intra-molecular linkages
between amino acid sulfhydryl groups of RNA, DNA and
proteins, leading to damage to these molecules. The LPO
products stimulate DNA repair processes and activate
polymerase leading to the depletion of NAD and ATP.
When peroxidation damage exceeds the repair process, it
will finally lead to cell death [37]. Many cancer cells were
killed by the PUFA-generated ROS, although the killing
mechanisms varies based on the cell type involved.
Higher concentrations of PUFAs increase the sensitivity to
ROS in tumor cells because of the cytotoxicity of LPO and
its metabolites [38]. Hence, because our studies were per-
formed in vivo, and MDA was measured in serum, a direct
link would be difficult to be drawn. Thus, some previous
studies have indicated an increase in ROS with DHA
administration [39]. However, in the present study, we
found a significant decrease in serum MDA levels in the
animals treated with DHA, either alone or in combination
with CP, as compared to the EAC-control group. This was
in agreement with earlier studies [40]. This reduction in
MDA level in groups treated with DHA may be explained
on the basis that the free radicals produced at site of actionCell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
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induce a marked, systematic anti-oxidant response as a
feedback to oxidative stress. This increase in anti-oxidants
would augment anti-oxidative potency in tissues and thus
eventually decrease LPO, resulting in the suppression of
end products of LPO, such as MDA. These prepositions
are in line with others that showed protective effect for
DHA on LDL oxidizability [41]. In addition, DHA was
found to suppress the expression of iNOS gene, and the
production of NO [42]. Our finding that DHA enhanced
GSH levels in renal tissues may support this view as well.
It is also important to notice that we did not find a signif-
icant positive association between serum MDA levels and
tumor size in this study. This suggested that serum levels
of MDA, in vivo, may well vary from those obtained in
tumor cells through in vitro studies. It is not also unrea-
sonable to assume that interaction of PUFAs or their
metabolites with additional signaling pathways could
contribute to their in vivo chemopreventive effects [43].
In the present study, a single CP dose (10 mg/kg, injected
IP on the 4th day) induced lethal nephrotoxicity in rats
after a total of 7 days. Because of the wide use of CP in
clinical settings, several pathological and toxicological
studies have investigated the underlying mechanisms of
such CP-induced nephrotoxicity. It was generally agreed
that the platinum content of CP is the main trigger of
these anomalies. Kidneys tend to accumulate and retain
platinum complexes to a greater extent than other organs,
and it is also the main excretory outlet for CP when given
by the IV or IP routes [44]. Ultimately, these events cause
renal tubular damage and dysfunction, proteinuria, and
wasting of sodium, potassium, and magnesium. Notably,
approximately 25–35% of patients develop evidence of
nephrotoxicity following a single dose of cisplatin [45].
On the contrary, the exact cellular and molecular under-
pinnings of such CP-evoked nephrotoxicity remain largely
to be unfolded. The reason of this ambiguity is that CP
interacts with several intracellular pathways. Examples
encompass gene modulations, activation of mitogen-acti-
vated protein kinases, induction of apoptosis, stimulation
of inflammation and fibrogenesis, depletion of L-carni-
tine, and induction of cytotoxicity by promoting the accu-
mulation of ROS. Thus, out of this plethora of reactions,
the adoption of an exact scenario appears to be a difficult
task [45]. Nevertheless, evidence from both in vitro and in
vivo studies was presented to testify for a prime contribu-
tion of reactive oxygen metabolites in the pathogenesis of
this nephrotoxicity. In this vein, CP was shown to gener-
ate ROS, such as superoxide anion and hydroxyl radicals,
and stimulate renal LPO accumulation [26]. The role of
LPO and its position in the chain of events that leads to
CP nephrotoxicity remains, however, controversial.
One of the most important intracellular anti-oxidant
defense systems is the glutathione redox cycle. Reduced
glutathione (GSH) is an essential component in main-
taining cell integrity because of its reducing properties as
well as its contribution to some essential cellular meta-
bolic pathways [46]. Many previous studies showed that
CP consistently depleted GSH, while elevated MDA levels,
as compared to baseline levels [47-49]. However, other
studies found that CP did not cause any significant change
in kidney levels of MDA, yet still caused a significant ele-
vation in endogenous GSH content of the kidney [50].
Therefore, this work represented an intriguing challenge
for DHA to alleviate this CP-evoked nephrotoxicity. Our
rational was based on reported cellular protective ability
for DHA in some models. For instance, DHA supplement
improved spatial cognition in rats, following transient
forebrain ischemia [51]. Also, in the renal system, PUFA
were found to protect against the renal tubular injury
caused by shiga toxin. The latter toxin can modulate cer-
tain intracellular pathways, thereby inducing cell death
[52]. Likewise, DHA inhibited mesangial cell activation
and proliferation, and reduced proteinuria, two primary
antecedents in the development of glomerular damage
[53]. In addition, DHA significantly alleviated the doxoru-
bicin-induced apoptosis of renal cortex cells [54]. The
present study was, however, the first to describe protective
effects for DHA against CP-induced nephrotoxicity in rats.
DHA (250 mg/kg; but not 125 mg/kg), given prior to and
concurrently with CP, attenuated CP-induced nephrotox-
icity, improved renal glomerular function, and obliterated
almost 90% of animal fatalities. Also currently, remarka-
ble anti-oxidant potential was produced by DHA in the
kidney homogenates. Thus, GSH level was significantly
increased; and MDA level was decreased from CP-treated
animals. Further, the results of correlations we made
between the levels of MDA or GSH in kidney homoge-
nates, and kidney glomerular function in terms of serum
creatinine strongly implicate oxidant stress in mediating
this type of nephrotoxicity (r = 0.81, -0.82).
Conclusion
The present study assessed the chemopreventive potential
of docosahexaenoic acid (DHA) and its impact on that of
CP in the EAC-implanted solid tumor model in mice.
Besides, it examined the mediatory role of oxidative stress,
represented by lipid peroxides (LPO) and the possible
diagnostic/prognostic role of CRP in the process of tum-
origenesis. Lastly, because of the pronounced CP-induced
nephrotoxicity in mammals, we also probed whether
(and how) the concurrent administration of DHA would
alleviate such serious adverse reaction to CP. The chemo-
prevention elicited by DHA was dose-dependent, and
appear to be mediated by reduction of leukocytosis, oxi-
dative stress, and replenishing of endogenous antioxidant
machinery. Most strikingly, a strong anti-inflammatory
effect was produced that was highly reflected by reduction
in CRP level. We provided a novel, strong evidence thatCell Division 2009, 4:6 http://www.celldiv.com/content/4/1/6
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CRP serves as a sensitive diagnostic/prognostic marker
both for tumor progression and responsiveness to chem-
otherapy in solid tumors.
In ischemic acute renal injury, inflammatory pathways
appear to play an important pathogenic role, and a high
level of cross-talk seems to exist between oxidant stress
and inflammation in these settings [2]. For instance, oxi-
dant stress, as in cisplatin-induced injury, activates the
NFκB transcription factor, which in turn promotes the
production of proinflammatory cytokines, including TNF-
α [55]. We currently confirmed this signaling system and
further challenged the capacity of DHA to downregulate
this pathway. DHA 250 mg/kg managed to blunt the
increment in TNF-α evoked by CP to near control values
and rescued 90% of the animals from the evidently lethal
CP nephrotoxicity. These findings correlated very well
with data for GFR and creatinine levels (r = 0.92); thus
attesting to a new mechanism of renal protection by DHA.
It is worthwhile verifying the clinical relevance of the cur-
rent findings on the basis of comparing the DHA doses
used in rat and mice to those used in human clinical trials.
In the latter studies, DHA has been used in a range of 26–
56 mg/kg/day [56]. These doses, based on dosage conver-
sion schemes, are equivalent to (165–347 mg/kg/day) in
rats and (320–690 mg/kg/day) in mice [57]; thus quite
comparable to the range used in this study (125–250 mg/
kg/day). Therefore, based on the animal/human dose rel-
evance, and clinical studies for the chemo-enhancing pro-
files of DHA in humans, the current findings suggest a
clinical chemopreventive/renal protective significance.
In essence, the renal protective and animal rescuing effects
obtained for DHA, as well as its capacity to ameliorate leu-
kocytosis, oxidant stress and inflammation, further sub-
stantiate its produced chemoprevention/chemo-
enhancing profiles. This could, therefore, suggest a new
fruitful drug regimen in the management of solid tumors
based on combining CP with DHA. Similar studies for
DHA with other antineoplastic drugs are also warranted.
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